When SAFEs Aren't Safe: What Every Founder Must Know

SAFEs have dominated early-stage fundraising for over a decade, but the bloom is off the rose for many institutional investors. Understanding exactly why — and what the alternatives look like — is now table stakes for any founder about to raise a pre-seed or seed round.

What a SAFE Actually Is

Y Combinator developed the Simple Agreement for Future Equity in 2013 to give early-stage founders a fast, low-cost way to raise money before a company had a defensible valuation. The instrument has four negotiable terms and skips the rest:

1. Discount — investor receives a reduced price on the next round's valuation (typically 20%)
2. Valuation cap — protects the investor if the company raises at a much higher valuation later
3. Financing threshold — the amount that triggers automatic conversion to equity
4. Most Favoured Nation (MFN) clause — adjusts the SAFE to match more favorable terms offered in future SAFEs

No valuation is set. No lawyers are required. No board seats change hands. That simplicity is the whole point — and the whole problem.

The Real Advantages

Speed and cost savings are genuine. Because valuation isn't on the table, SAFEs close without the negotiation overhead of a priced round.

For friends-and-family checks, the format is ideal. Supporters who believe in the founder but can't navigate cap table mechanics or term sheet negotiations get a clean, readable document.

That said, simplicity has a ceiling.

Five Risks Investors (and Founders) Should Take Seriously

The SAFE's stripped-down structure creates genuine exposures that become clearer as a company matures. The VC Factory and DLA Piper have both documented the friction these instruments create for investors at scale.

1. No Control Rights

SAFE holders have no voting rights, no board representation, and no formal mechanism to influence company decisions. They are passive by design. That's fine for a small angel writing a $25K check; it's a material concern for a fund deploying six or seven figures.

2. Valuation Uncertainty

Because no company valuation is set at signing, investors don't know what percentage they will actually own. The cap limits the worst-case scenario but doesn't guarantee a fair price. The investor's effective ownership is only knowable at the moment of conversion — which could be years away.

3. Dilution Risk

SAFEs carry no anti-dilution provisions. If the founder issues more SAFEs, or raises additional rounds before conversion, early SAFE holders get diluted with no contractual recourse. They won't know how much of the company they own until the cap table is finally set at a priced round.

4. Complexity Creep from Side Letters

The base SAFE template is clean. In practice, many investors layer on side letters and custom terms for protection. The result is a priced-round level of complexity without the pricing, the diligence process, or the lawyers. Founders often sign these additions without fully understanding the downstream consequences — which is precisely the scenario that argues for legal review even when the instrument was designed to avoid it.

5. No Expiration Date

A SAFE sits on your cap table indefinitely. If the company never completes a priced round or exit, the investor never converts — and never receives shares. Some SAFEs have tried to address this with additional terms, but that pushes the instrument back toward the complexity founders were trying to avoid in the first place.

The Numbers Behind the Trend

SAFEs remain widely used despite these drawbacks. In 2022 online startup investing (Reg CF and Reg A+), 414 out of 1308 equity deals were SAFEs — roughly 32% of all equity transactions. The instrument isn't disappearing, but institutional investors are increasingly steering founders toward alternatives.

Why VCs Are Moving Toward Convertible Notes

The convertible note is a hybrid debt-equity instrument. The investor lends money to the company and receives the right to convert into equity at a later date, typically at a discount or against a cap — mechanics that look similar to a SAFE on the surface.

The critical difference is the debt floor.

If the company never raises a priced round, the investor is still owed their money as a creditor. SAFE holders get nothing in that same scenario.

That legal recourse changes the risk profile entirely for institutional investors. Convertible notes add modest complexity — maturity dates, interest rates, default provisions — but that complexity buys investors meaningful downside protection.

How to think about which instrument to use:

What Founders Should Do Before Signing

The SAFE's simplicity is a feature at the right stage with the right investors. But it isn't a reason to skip diligence on your own documents.

Before you close any SAFE or convertible note:

• Read the MFN clause carefully — it can pull earlier investors into better terms you offer later without your explicit consent
• Review any side letters with a lawyer, even if the base SAFE doesn't require one; the additions often do
• Know your total SAFE overhang before pitching a Series A — stacked unconverted SAFEs can create messy cap tables that spook institutional investors
• If an investor is asking for terms beyond the standard four, ask whether a convertible note or priced round is actually cleaner for both sides

The SAFE is still the right tool for fast, small checks from investors who trust the founder and don't need control mechanisms. For larger checks or investors asking for structural protections, the convertible note or a priced round will save friction later.

When you're unsure how a term affects your company — ask Bowery Legal or another startup-focused attorney before signing. The instrument was designed to avoid lawyers, but that doesn't mean you should.

Further reading: The VC Factory on SAFE problems · DLA Piper's SAFE explainer · Crowdwise on whether SAFEs are bad for investors